Mylan to cover up to $300 of out-of-pocket cost of EpiPen at pharmacy

In the face of ongoing criticism of price gauging, Netherlands-based generics major Mylan (Nasdaq: MYL) today announced it is taking immediate action to further enhance access to EpiPen(epinephrine) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs.

The company is reducing the patient cost of the EpiPen Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak. For patients who were previously paying the full amount of the company's list price for EpiPen, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families as well.

Criticism from Senators and Hillary Clinton